Literature DB >> 19050159

Chronic cannabinoid administration in vivo compromises extinction of fear memory.

Hui-Ching Lin1, Sheng-Chun Mao, Po-See Chen, Po-Wu Gean.   

Abstract

Endocannabinoids are critically involved in the extinction of fear memory. Here we examined the effects of repeated cannabinoid administration on the extinction of fear memory in rats and on inhibitory synaptic transmission in medial prefrontal cortex (mPFC) slices. Rats were treated with the CB1 receptor agonist WIN55212-2 (WIN 10 mg/kg, i.p.) once per day for 7 d. On day 8, the rats were submitted to a standard fear conditioning procedure, and retention of memory was measured with potentiated startle paradigm. We found that (1) WIN-pretreated rats exhibited much less extinction to cue alone presentations; (2) the reduction of fear-potentiated startle normally seen when the CB1 receptor agonists were infused into the mPFC was absent in the WIN-pretreated rats; (3) WIN-induced inhibition of GABAergic transmission was significantly less in slices from the WIN-pretreated rats than that from the vehicle-pretreated control; (4) WIN failed to induce extracellular signal-regulated kinases (ERKs) phosphorylation in the WIN-pretreated rats; and (5) the level of CB1 receptor in the WIN-pretreated rats was lower than that of vehicle-pretreated rats. These results suggest that endocannabinoids within the mPFC play an important role in the extinction of conditioned fear. However, long-term marijuana use may limit its clinical efficacy for the treatment of anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050159     DOI: 10.1101/lm.1081908

Source DB:  PubMed          Journal:  Learn Mem        ISSN: 1072-0502            Impact factor:   2.460


  24 in total

Review 1.  Neural and cellular mechanisms of fear and extinction memory formation.

Authors:  Caitlin A Orsini; Stephen Maren
Journal:  Neurosci Biobehav Rev       Date:  2012-01-02       Impact factor: 8.989

Review 2.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

3.  CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model.

Authors:  Guangchen Ji; Volker Neugebauer
Journal:  Eur J Neurosci       Date:  2014-02       Impact factor: 3.386

Review 4.  Sex differences in fear extinction.

Authors:  E R Velasco; A Florido; M R Milad; R Andero
Journal:  Neurosci Biobehav Rev       Date:  2019-05-23       Impact factor: 8.989

5.  Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans.

Authors:  Christine A Rabinak; Mike Angstadt; Maryssa Lyons; Shoko Mori; Mohammed R Milad; Israel Liberzon; K Luan Phan
Journal:  Neurobiol Learn Mem       Date:  2013-09-19       Impact factor: 2.877

Review 6.  Seeking a spotless mind: extinction, deconsolidation, and erasure of fear memory.

Authors:  Stephen Maren
Journal:  Neuron       Date:  2011-06-09       Impact factor: 17.173

Review 7.  Pharmacological enhancement of fear reduction: preclinical models.

Authors:  Bronwyn M Graham; Julia M Langton; Rick Richardson
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

8.  Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2.

Authors:  Sabrina Francesca Lisboa; Anzela Niraula; Leonardo Barbosa Resstel; Francisco Silveira Guimaraes; Jonathan P Godbout; John F Sheridan
Journal:  Neuropsychopharmacology       Date:  2018-04-17       Impact factor: 7.853

9.  Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Neuropsychopharmacology       Date:  2014-09-01       Impact factor: 7.853

Review 10.  Post-traumatic stress disorder: emerging concepts of pharmacotherapy.

Authors:  Dewleen G Baker; Caroline M Nievergelt; Victoria B Risbrough
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.